Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology
Treating hypertension is known to decrease morbidity and mortality. Despite this 70% of patients do not have adequately controlled blood pressure. The main reason for this is non-adherence to recommended drug therapy. Although strategies have been developed to improve adherence many are time consuming and expensive. We propose to use communications technology to develop a novel means of improving adherence to antihypertensive therapy. We will conduct a randomised, single-blinded, controlled study to assess the impact of a real-time, automated reminder system on adherence rates. This will involve adapting two pieces of currently available technology - the electronic pill bottle and the Ambient Globe. The Globe will change colour in response to information received, via a wireless link, from the patient's electronic pill bottle. We hypothesise that this will provide patients with an up to date, but unobtrusive, reminder of their adherence status and thus effect positive behavioural change. We will measure the impact of this intervention on adherence rates as well as assessing patient views and the impact on provider workload. This trial will elucidate the role of communications technology in improving adherence behaviour and allow us to develop further strategies to tackle this major health issue.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind
|Official Title:||Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology|
- Adherence rates as measured using data held in the SIMpill database
- Patient satisfaction with intervention as assessed by questionnaire at the end of the study.
- Technical difficulties as assessed by interview at the end of the study and by review of the technical log.
- Discontinuation rates of medication as assessed at the end of trial debrief.
- Changes to medication regime as assessed at the end of trial debrief.
- Adverse events (e.g. hospitalisation) as assessed from the log of withdrawals from the trial.
- Blood pressure as measured on enrollment and at end of trial debrief.
|Study Start Date:||July 2006|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00277381
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Joseph C. Kvedar, MD||Partners Healthcare System|